Navigation Links
Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel

NEWTON, Mass., Jan. 22, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, has announced a financing arrangement with Schooner Capital, a Boston-based investment firm.  The agreement provides Topokine with immediate capital and the ability to draw additional capital to advance the Company's pipeline, including XAF5 Gel, a clinical-stage skin cream for local reduction of excess subcutaneous fat.  Specific terms were not disclosed.

"We are delighted to partner with Schooner Capital," said Murat Kalayoglu, MD, PhD, Topokine President and CEO.  "Schooner's long-term commitment allows us to invest not only in the development of XAF5 Gel, but also other drugs in our pipeline."

"Topokine is generating impressive results and intellectual property at a rapid pace," said Ted Henderson , a Managing Director at Schooner Capital.  "We are committed to seeing Topokine's products get to market, whether by organic growth or with a best-in-class Pharmaceutical partner."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About Schooner Capital

Founded in 1971, Schooner Capital is a Boston-based private investment firm.  The firm approaches all investments with a long-term perspective and invests in private companies across stage and sector, with a focus on quality of management, unit economics, and long-term growth prospects.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are based on current beliefs and expectations, but actual results may differ.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc.,,

News distributed by PR Newswire iReach:

SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
2. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
3. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
4. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
5. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
6. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
7. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
8. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
9. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Echo Therapeutics Announces Proposed Public Offering
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... medical opinion process, participated in the 61st annual Employee Benefits Conference. The Employee ... took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
Breaking Medicine News(10 mins):